Why the study?
Does adenosine stress testing induce changes in serum H-FABP levels in patients with stable coronary artery disease?
Observational (n=30)
Does adenosine stress testing induce changes in serum H-FABP levels in patients with stable coronary artery disease?
H-FABP levels do not change significantly during pharmacologic stress testing in patients with known coronary artery disease, regardless of the presence of inducible ischemia.
BACKGROUND: Heart-type fatty acid-binding protein (H-FABP) is a marker of myocardial necrosis, but whether it increases during myocardial ischemia is not known. This study investigated whether serum levels of H-FABP change during adenosine stress testing and nuclear imaging in patients with stable coronary artery disease. METHODS: Thirty stable patients with established coronary artery disease on their medications were studied. Sampling was performed before the stress test, at the end of adenosine infusion, as well as 1, 2 and 3 h after the completion of the infusion. RESULTS: No difference in H-FABP serum levels were found at the five pre-specified time points in the overall group (p=0.99); furthermore, there was no significant difference regardless of the test result--positive (p=1) or negative (p=0.98). CONCLUSIONS: It is concluded that H-FABP does not change significantly during pharmacologic stress testing in patients with known coronary artery disease and there is no difference whether there is inducible ischemia or not.
No takes yet. Share an insight, caveat, or question.
Sbarouni et al. (2011) conducted an observational in stable coronary artery disease (n=30). Adenosine stress testing was evaluated on Change in serum levels of H-FABP at five pre-specified time points (p=0.99).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: